Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from uniQure

Huntington's Disease Gene Therapy AMT-130 Is on Track for FDA Approval After uniQure Reaches Regulatory Agreement

uniQure announced June 17, 2026: FDA agreed that 3-year AMT-130 Phase I/II data supports an accelerated approval BLA for Huntington's disease. BLA submission planned Q3 2026.

Medical Daily

uniQure Stock Looks Drastically Undervalued After Upbeat FDA Meeting

uniQure stock looks poised to soar over the long term, but it does pose meaningful risk.

Barchart

Breakout Momentum Plays You Need to Know About

Three stocks may draw the attention of momentum investors—QURE spiked in September, OMER in October, and SDST has almost 1,000% in upside potential.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Cramer Warns On One Chip Stock, Says Broadcom Is The Better Bet

On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended being careful with Ambiq Micro, Inc. (NYSE:AMBQ). He added, “There are so many good semiconductor companies out there” and recommended going with Broadcom (NASDAQ:AVGO).

Benzinga

QURE: Why Analysts See Up to 63% Upside After 250% Single-Day Pop

Biotech stock uniQure just popped nearly 250% in one day, with an analyst calling its trial results "amazing". Wall Street sees significant upside to come.

MarketBeat

A new treatment for Huntington’s disease is genuinely promising – but here’s why we still need caution

Imagine knowing in your 20s or 30s that you carry a gene which will cause your mind and body to slowly unravel. Huntington’s disease is inherited, relentless and fatal, and there is no cure. Families live with the certainty of decline stretching across generations.

The Conversation

New hope for Huntington’s families as gene therapy shows remarkable results

A company called uniQure has announced promising results from a trial of a new gene therapy for Huntington’s disease. The news has spread quickly through families affected by this condition, who have been desperately waiting for a treatment that can stop or slow down this devastating illness.

The Conversation

Read news from The Economist, FT, and more,
with one subscription

UniQure Stock's 248% Blastoff Was Just The Start — Ask Wall Street

UniQure NV (NASDAQ: QURE) just staged one of biotech's wildest rides of the year, soaring 248% in a single session after unveiling successful trial results for its experimental Huntington's disease gene therapy. Indeed, the stock reached a 5-year high, marking its best session ever. But if you think the move…

Benzinga

Doctors say experimental gene therapy seems to slow Huntington’s disease for first time

It is the first time a drug trial has slowed the rare disorder’s progression in an ongoing, significant way, researchers said.

Euronews

Alibaba, Intel, Uniqure, Tesla And Opendoor: Why These 5 Stocks Are On Investors' Radars Today

U.S. stocks slipped on Wednesday, with the Nasdaq losing more than 75 points, or 0.3%, to close at 22,497.85. The Dow Jones Industrial Average declined 0.37% to 46,121.28, while the SP 500 eased 0.3% to 6,637.97.

Benzinga

This Stock Is Tripling on a Key Gene Therapy Win. Should You Buy the 200%-Plus Surge Now?

Uniqure shares skyrocket as the biotech firm announces a major breakthrough in Huntington’s disease. Here’s why investors should wait before initiating a new position in QURE stock.

Barchart

What's Going On With UniQure Stock Wednesday?

UniQure N.V. (NASDAQ:QURE) shares are trading higher Wednesday after the company announced positive topline results from Phase I/II study of AMT-130 in patients with Huntington’s Disease.

Benzinga

'Groundbreaking' gene therapy is first treatment for Huntington's disease to slow the condition

Results from a three-year trial suggest an experimental gene therapy for Huntington's disease can slow the progression of the deadly condition by 75%.

LiveScience

First Successful Gene Therapy for Huntington's Disease Slows Disease Progression by 75%

In a landmark clinical trial, uniQure's gene therapy AMT-130 slowed Huntington's disease progression by 75% over 3 years. The one-time treatment may mark the first disease-modifying therapy for this incurable neurodegenerative condition.

Medical Daily

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

uniQure Stock Doubles On Promising Data From Huntington's Disease Trial

uniQure N.V. (NASDAQ:QURE) on Wednesday released topline data from the pivotal Phase 1/2 study of AMT-130 for Huntington’s disease.

The Guardian - UK

Huntington’s disease treated successfully for first time in UK gene therapy trial

Surgical procedure to treat devastating illness slowed progress of disease by 75% in patients after three years

Evening Standard

Huntington’s disease slowed for first time by 'groundbreaking' new treatment

University College London experts say the finding could ‘change everything’ for patients with the condition

Benzinga

uniQure's Investigational Gene Therapy Shows Promising Efficacy With Manageable Safety Risks For Fabry Disease

uniQure N.V. (NASDAQ:QURE) on Friday released initial safety and exploratory efficacy data from the first cohort of its Phase 1/2a trial of AMT-191, an investigational gene therapy for Fabry disease.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

UniQure Shares Are Up After Low-Dose Cohort Data From Huntington's Gene Therapy Trial

UniQure N.V. (NASDAQ:QURE) announced safety and biomarker data from 10 patients enrolled in the low-dose cohort of the ongoing Phase 1/2 trial of AMT-130 gene therapy for Huntington's disease. Six of the ten enrolled patients received AMT-130, and four received an imitation surgical procedure in this randomized, blinded clinical trial in the U.S.…

Benzinga

Mizuho Comments On UniQure's Upcoming Low-Dose Huntington's Gene Therapy Trial Data

The much-awaited one-year data for the entire low-dose cohort for UniQure NV's (NASDAQ: QURE) AMT-130 gene therapy in Huntington's disease is expected at any time.

Benzinga

Analyst Ratings for uniQure

Within the last quarter, uniQure (NASDAQ:QURE) has observed the following analyst ratings:

Benzinga

Recap: uniQure Q1 Earnings

uniQure (NASDAQ:QURE) reported its Q1 earnings results on Monday, May 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

Overview Of Value Stocks In The Healthcare Sector

Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

Benzinga

uniQure: Q4 Earnings Insights

uniQure (NASDAQ:QURE) reported its Q4 earnings results on Friday, February 25, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings uniQure reported an EPS of $0.17.

People

Jim Cramer

515 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.